This surge has increased demand for treatments, diagnostic tools, and therapies, prompting advancements in pharmaceuticals and healthcare solutions. Ongoing research, improved early detection methods, and innovative therapies further contribute to the segment’s market dominance. Pharmaceutical R&D spending has been a pivotal driver of market growth, with the sector continuously investing in the discovery and development of new therapies. Major companies such as Johnson & Johnson, Merck, and Eli Lilly have earmarked significant portions of their revenues to R&D, recognizing the importance of developing innovative drugs to meet the demands of an aging population and the increasing prevalence of chronic diseases. The biologics & biosimilar segment is expected to grow at a CAGR of 6.83% during the forecast period.The biosimilar segment has seen high adoption and widespread product availability due to increased acceptance from both healthcare providers and patients. These biologic drugs offer a cost-effective alternative to original biologics, providing the same therapeutic benefits at lower prices.
The presence of a robust product portfolio and diverse distribution network of these players across key applications such as immunology, oncology, and vaccines propel their company share in the market. Thus, the growing adoption of AI-based tools for drug discovery is likely to trigger the demand of the US pharmaceutical market analysis during the forecast period. The research-based pharmaceutical industry is an important asset of the European economy; it is one of the top-performing high-technology segments in the region. As per the European Federation of Pharmaceutical Industries and Associations (EFPIA), the research-based pharmaceutical industry in Europe invested ~US$ 44,266.18 million (€ 41,500 million) in R&D in 2021. Similarly, governments of countries in Asia Pacific are focusing on pharmaceutical R&D activities. The market for pharmaceutical oncology is changing significantly despite the anticipated increase.
US Pharmaceutical Market Trends
By distribution channel, the hospital pharmacies segment is anticipated to show lucrative growth in the market over the coming years. The segmental growth is attributed to the presence of trained professionals and the increasing number of hospitalizations. Hospital pharmacies contain all the medicines that are prescribed by healthcare professionals. This platform contains insights related to the latest global, regional and subregional estimates and trends in drug demand and drug supply in the form of global, regional and sub-regional Key Findings that are easy to search. The user can explore the key findings sequentially following a narrative by their topic of choice.
Government And Regulatory Tailwinds
- As reported by ASPE, between 2016 and 2021, there was a consistent decrease in retail generic drug expenditures, while non-retail generic drug expenditures showed a steady rise.
- Cuba stopped being a center for transport of cocaine following the Cuban Revolution and the establishment of Fidel Castro’s communist government in 1959.
- Therewere 209 biological products on the market in 2017, which increasedto 268 in 2022 (28 percent increase).
- According to the CDC’s National Diabetes Statistics Report for 2020, 26.8 million people are living with diabetes, indicating a significant need for prescription medications to manage and treat chronic diseases, thereby contributing to growing demand.
- The growing availability of prescription drugs and the rising need for daily medications, such as anti-diabetics, are some of the major factors responsible for the growth of this segment over the forecast period.
This divergence forces global players to operate not as single monolithic entities, but as a federation of highly specialized regional businesses, each tailored to the unique demands of its local market. By route of administration, the injections segment will gain a significant share of the market over the studied period. Generic injections have the major advantage of increased bioavailability as they reduce systemic side effects.
- As a result, wecannot examine the costs borne by patients via copays or coinsurance fordrugs resulting from low competition.
- Also, in North America, especially the US, they greatly emphasize on patient-oriented, convenient delivery system and expenditure on healthcare resources.
- The hospital pharmacy segment dominated the peptide drug conjugates market with a revenue share of 53.53% in 2024 due to increasing hospital admissions, rising demand for specialized treatments, and access to a wide range of prescription medications.
- Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets.
Highest Priced Drugs
Around the world, an increasing geriatric patients with chronic conditions like cardiovascular diseases, diabetes, and cancer, with technological advancements in drug development, are driving the market growth. North America dominated this market in 2024, by majorly impacting factors like the adoption of technological advancements like targeted therapies and biologics with personalized medicine as well. The oncology segment held the highest U.S. prescription drugs market share among therapy areas. The highest share was attributed to the rise in the prevalence of cancer among the U.S. population and the increasing emphasis of key players on the introduction of new drugs for various indications in the market.
Distribution Channel Market Insights
You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs. I requested a report on a very specific software market and the team produced the report in a few days. I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
Additionally, the American Society of Health-System Pharmacists (ASHP) reported that the total drug spending in the country increased by around 8% in 2021, further indicating the high demand for prescription drugs in the country. The pharmaceutical market in France is fueled by government healthcare initiatives and increased adoption of biologics and specialty drugs. Rising prevalence of chronic diseases and the growing need for effective therapies support market expansion.
Conclusion: COVID-19 Abates, Specialty Drugs Dominate, And Biosimilars Promise Growth
As the demand for prescription drugs continues to rise, it is likely to create new opportunities for pharmacies to expand their offerings and cater to the needs of patients with chronic illnesses. This growth is expected to benefit the industry in the long term by increasing revenue streams and improving healthcare outcomes for patients. The market in Europe accounted for the second largest share in the global market, and reasons for the region’s strong market share include increased demand for advanced prescription products and the product launches of efficient prescription products, including orphan drugs. Furthermore, several market players are introducing generic drugs to provide affordable treatment across the region. In terms of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies. Some of the key reasons for the dominance of the hospital pharmacies segment is that the therapeutics indicated under prescription drugs can often be only prescribed in hospital settings under the guidance of trained medical professionals.
How Did The Hospital Pharmacies Segment Lead The Market In 2024?
PresidentBiden’s Executive Order 14036, “Promoting Competition in theAmerican Economy” identified a lack of competition as a key driverfor problems across economic sectors. By incentivizing competition, it ispossible to foster innovation and improve the stability of a market, in turnincreasing access and affordability of products. The U.S. prescription drugmarket is the largest drug market in the world; however, drug prices in theU.S. High drug prices mean thatpeople often cannot afford prescription drugs, even when those drugs areotherwise available. By increasing competition, standard economic theorysuggests that the price of drugs will decrease, and more Americans will haveaccess to affordable prescription drugs.
Yet in many respects, conditions in the markets for illegal drugs seem to dramatically depart from the textbook model. In fact, demand for heavily addictive substances is consistent with a wide range of price elasticities. Suppose, for example, that an individual spends every cent of her monthly income on crack cocaine. If crack cocaine prices rise by 1 percent with no accompanying change in her economic circumstances, she will spend the same amount and thus purchase 1 percent less crack than she did before. Luksetich and White (1983) suggest, based on early ethnographic work, that heroin addicts may have a fixed budget for all items other than heroin, representing the minimum that is needed for shelter, food, and clothes; if so, there would be unitary price elasticity. In contrast, more affluent users of marijuana, for whom the drug accounts for a small share of their total incomes, may change their total consumption very little in response to price increases.
At present, around 620 million people worldwide are living with heart and circulatory diseases, and it is estimated that around 60 million new cases of cardiovascular diseases are reported annually. Off-patent and off-exclusivity drugs refer to pharmaceutical products that have lost their patent protection or exclusivity rights. Generic drugs are typically more affordable than their brand-name counterparts and provide similar therapeutic effects. The availability of off-patent and off-exclusivity drugs contributes to increased accessibility to essential medications and competition in the pharmaceutical market. The generic drugs segment is anticipated to grow at the fastest CAGR of 7.4% from 2025 to 2032, driven by patent expirations, increasing demand for cost-effective treatments, and favorable regulatory support. The high patient preference for oral route administration and cost-effectiveness of manufacturing oral formulations further bolstered the segment growth.
The national overdose growth rate, remarkably constant over the period and roughly doubling every eight years, is apparently impervious to shifts in policy interventions. Even the emergence and decline of specific drugs has little effect; deadly as fentanyl is, statistically, it looks merely like an extension of what was even in 2015 a 35-year trend. Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry.
